For general inquiries, call 1 877-564-0008 or [email protected]. Fax PoNS device prescriptions to 1 (215) 754-4903.

Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference

Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference September 21, 2023 at 7:05 AM EDT Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month NEWTOWN, Pa., Sept. […]

Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day

NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) – Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is excited to announce its participation in the prestigious Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.  The event, which coincides with the May 30 observance of World MS […]

Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

MS, Stroke and mmTBI Cover Broader Set of Indications Across North American Markets NEWTOWN, Pa., April 17, 2023 (GLOBE NEWSWIRE) – Helius Medical Technologies (NASDAQ: HSDT) today announced it will exhibit at the American Academy of Neurology (AAN) Annual Meeting for the first time since its Portable Neuromodulation Stimulator (PoNS) device became commercially available in […]

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

– Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis – NEWTOWN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, […]

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) – Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS®) into the hands of qualified Americans with multiple sclerosis (MS) at a significantly reduced cost. This initiative, the Patient […]

Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps NEWTOWN, Pa., Jan. 03, 2023 (GLOBE NEWSWIRE) – Helius Medical Technologies (NASDAQ: HSDT) launched a new e-commerce site that makes it easier for Americans experiencing issues with their gait to obtain the company’s innovative Portable Neuromodulation Stimulator (PoNS®). When combined with an […]

Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer and MGH Institute of Health Professions to its Therapeutic Experience Program

– Fourth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis – NEWTOWN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today […]

Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program

– Third Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis – NEWTOWN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, […]

Helius to Showcase Innovative PoNS Device at ACRM’s 2022 Conference – Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

Physical Therapists Who Visit Booth 512 Can Sign Up for Free Online PoNS Therapy™ Training NEWTOWN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies (NASDAQ: HSDT) will showcase its innovative new Portable Neuromodulation Stimulator (PoNS®) at the 99th annual American Congress of Rehabilitation Medicine (ACRM) Conference, held November 8-11 in Chicago. Visitors to […]

Helius Salutes Physical Therapists for Their Role in Helping People with MS Improve Their Gait

Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy Month NEWTOWN, Pa., Oct. 13, 2022 (GLOBE NEWSWIRE) – National Physical Therapy Month (NPTM) comes every October, but this one is particularly meaningful to Helius Medical Technologies (NASDAQ: HSDT): This year, the company has trained a […]

By submitting this form, you agree to receive future updates and communication regarding the PoNS® device and other Helius products, services, programs or topics of interest. Your consent is not required as a condition of receiving any goods or services from Helius. You may choose unsubscribe and choose not to receive further information from Helius by emailing [email protected]

IMPORTANT SAFETY INFORMATION

No serious adverse events related to the PoNS device were reported in the MS RCTs or in use in clinical rehabilitation settings to treat balance and gait disorders.

Some individuals have reported headaches, fatigue, and excess salivation. Excess salivation during training sessions often occurs but generally improves as patients get used to wearing the mouthpiece.

Indication
The PoNS® device is indicated for use as a short term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis and is to be used as an adjunct to a supervised therapeutic exercise program for adults 22 years of age and over by prescription only.

Contraindications
The PoNS® device delivers electrical stimulation directly to the surface of the tongue. Precautions for use are similar to those for transcutaneous electrical nerve stimulation (TENS).

Electrical stimulation should not be used:

  • If there is an active or suspected malignant tumor
  • In areas of recent bleeding or open wounds
  • In areas that lack normal sensation

The PoNS® has not been tested on, and thus should not be used by individuals who are pregnant. Do not use the PoNS® if you are sensitive to nickel, gold or copper.

Use with caution
Electrical stimulation should only be used after seeking professional medical advice, and with caution in patients with any of the following:

  • Implanted electronic devices, including:
    • Cardiac pacemakers
    • Cardioverter defibrillators
    • Deep Brain Stimulators
    • Vagal Nerve Stimulators
    • Sacral nerve stimulators
    • Cochlear Implants
  • Metal in the mouth (e.g. piercings, braces, retainers, or other orthodontic appliance)
  • Seizure disorders
  • Epilepsy

Ready to get started with PoNS?

Patients who are seeking more information on how to get PoNS can email us at [email protected], or fill out our contact form: